Temporal Effect of CYP3A4/5 Induction on Ticagrelor’s Pharmacodynamic Effects: A Case Series
Journal of Pharmacy Practice · 2025
DOI: 10.1177/08971900241273095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Thomas W Szymanski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, WVU Medicine, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inducers, Platelet Aggregation Inhibitors, Ticagrelor. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Ticagrelor is contraindicated in combination with cytochrome P450 3A4 and 3A5 enzyme (CYP3A4/5) inducers due to increased clearance, causing diminished antiplatelet effects. The emergent nature of acute coronary syndromes (ACS) may preclude scrutinization of home medications before P2Y 12 inhibitor administration. The purpose of this case series is to establish the temporal impact of CYP3A4/5 enzyme induction on ticagrelor’s pharmacodynamic effect by utilizing VerifyNow platelet aggregation studies. This was a retrospective case series of three patients who were taking a CYP3A4/5-inducing medication and loaded with ticagrelor for ACS. The duration of ticagrelor’s antiplatelet effect was dramatically shortened in the presence of background CYP3A4/5 induction. The offset of antiplatelet effect, defined by platelet reactivity units (PRU), was 10-24 hours in the presence of CYP3A4/5 enzyme induction compared to the anticipated 36-48 hours. This was consistent across CYP3A4/5-inducing medications including carbamazepine, phenobarbital, and phenytoin. This study demonstrates rapid return of platelet function after a ticagrelor loading dose in the presence of CYP3A4/5-inducing medications. Monitoring of PRU every 6-12 hours with subsequent loading with clopidogrel or prasugrel should be considered. Larger scale studies are warranted to confirm these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, WVU Medicine, Morgantown, WV, USA.
ORCID-Profile: Thomas W Szymanski, Matthew R Rockhold, Jordan L Lacoste
Zitieren
APA
Szymanski, T. W., Rockhold, M. R., & Lacoste, J. L. (2025). Temporal Effect of CYP3A4/5 Induction on Ticagrelor’s Pharmacodynamic Effects: A Case Series. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241273095
Vancouver
Szymanski TW, Rockhold MR, Lacoste JL. Temporal Effect of CYP3A4/5 Induction on Ticagrelor’s Pharmacodynamic Effects: A Case Series. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241273095
BibTeX
@article{Szymanski2025,
author = {Szymanski, Thomas W and Rockhold, Matthew R and Lacoste, Jordan L},
title = {Temporal Effect of CYP3A4/5 Induction on Ticagrelor’s Pharmacodynamic Effects: A Case Series},
journal = {Journal of Pharmacy Practice},
year = {2025},
doi = {10.1177/08971900241273095}
}
EUVIMED